Daniela De Nitto
University of Rome Tor Vergata
11 Papers
65 Citations
Daniela De Nitto is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Inflammation & Ulcerative colitis. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
Interleukin-21 triggers effector cell responses in the gut.
TL;DR: In the gut of patients with Crohn's disease and patients with ulcerative colitis, the major forms of inflammatory bowel diseases in humans, the tissue-damaging immune response is mediated by an active cross-talk between immune and non-immune cells.
42
Lesional accumulation of CD163-expressing cells in the gut of patients with inflammatory bowel disease.
Eleonora Franzè,Roberta Caruso,Carmine Stolfi,Massimiliano Sarra,Maria Laura Cupi,Flavio Caprioli,Ivan Monteleone,Francesca Zorzi,Daniela De Nitto,Alfredo Colantoni,Livia Biancone,Francesco Pallone,Giovanni Monteleone +12 more
TL;DR: Findings indicate that IBD mucosa is abundantly infiltrated with CD163-positive cells, which could contribute to amplify the inflammatory cytokine response.
Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases.
TL;DR: The available data supporting the pathogenic role of IL-23 and Th17-related cytokines in IBD are reviewed, and whether and how compounds that control the activity of these cytokines may enter into the therapeutic armamentarium of IBD is discussed.
35
Biological therapy for dermatological manifestations of inflammatory bowel disease.
TL;DR: The therapeutic effects of the two most widely used anti-TNF-α molecules, infliximab and adalimumab are reviewed, for the treatment of the major cutaneous manifestations associated with IBD (EN, PG and psoriasis).
31
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis
Roberta Pica,Claudio Cassieri,A. Cocco,Maddalena Zippi,Adriana Marcheggiano,Daniela De Nitto,E.V. Avallone,P. Crispino,G. Occhigrossi,Paolo Paoluzi +9 more
TL;DR: In ulcerative colitis patients younger than 40 years and/or with extensive disease, a daily dose of 4.8 g oral mesalazine results in increased rates and duration of remission compared to 2.4 g.
28